Begelomab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Begelomab
Accession Number
DB13241
Type
Biotech
Groups
Experimental, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
360N6PY2A1
CAS number
1403744-56-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Begelomab.
AlclometasoneThe risk or severity of adverse effects can be increased when Begelomab is combined with Alclometasone.
AldesleukinThe risk or severity of adverse effects can be increased when Begelomab is combined with Aldesleukin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Begelomab.
AmcinonideThe risk or severity of adverse effects can be increased when Begelomab is combined with Amcinonide.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Begelomab.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Begelomab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Begelomab is combined with Anthrax immune globulin human.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Begelomab.
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Begelomab is combined with Bacillus calmette-guerin substrain connaught live antigen.
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
L04AA35 — Begelomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on August 02, 2018 06:49